Unique in vitro and in vivo thrombopoietic activities of ingenol 3,20 dibenzoate, a Ca(++)-independent protein kinase C isoform agonist.
Thrombopoiesis following severe bone marrow injury frequently is delayed, thereby resulting in life-threatening thrombocytopenia for which there are limited treatment options. The reasons for these delays in recovery are not well understood. Protein kinase C (PKC) agonists promote megakaryocyte diff...
Main Authors: | Frederick K Racke, Maureen Baird, Rolf F Barth, Tianyao Huo, Weilian Yang, Nilendu Gupta, Michael Weldon, Heather Rutledge |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3528756?pdf=render |
Similar Items
-
Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
by: Gerald A Soff, et al.
Published: (2022-01-01) -
Tattoo removal with ingenol mebutate
by: Cozzi SJ, et al.
Published: (2017-05-01) -
Carica papaya induces in vitro thrombopoietic cytokines secretion by mesenchymal stem cells and haematopoietic cells
by: Aziz, J., et al.
Published: (2015) -
Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis
by: Yu Dong, et al.
Published: (2023-06-01) -
Ingenol mebutate–associated immune thrombocytopenic purpura
by: Hafsa Zuberi, BS, et al.
Published: (2024-04-01)